Lynparza gets FDA approval for ovarian cancer
Lynparza has been approved in the US for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer.
Read More
Tag: AstraZenca
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
